Screener
Omeros OMER PDE7 — Total Costs & Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Omeros in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The source filing: Omeros’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:07 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001437749-26-016720
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cost of product sales | 587 | — |
| Research and development | 13,358 | 23,846 |
| Selling, general and administrative | 13,369 | 11,123 |
| Total costs and expenses | 27,314 | 34,969 |
| Loss from operations | (17,421) | (34,969) |
| Interest and other income | 1,475 | 1,123 |
| Interest expense, net of remeasurement adjustments and other | (5,894) | (3,654) |
| Net gain (loss) on change in fair value of financial instruments | 73,146 | (65) |
Document
FAQ
- What is Omeros's PDE7 — total costs & expenses?
- Omeros (OMER) reported PDE7 — total costs & expenses of $575K in Q4 2026.
- How has Omeros's PDE7 — total costs & expenses changed year-over-year?
- Omeros's PDE7 — total costs & expenses increased by 4.5% year-over-year, from $550K to $575K.
- What does PDE7 — total costs & expenses mean?
- Captures the total operating costs directly attributable to the research, development, and administrative activities of the PDE7 product segment. This includes personnel costs, clinical trial expenses, and overhead allocated to advancing this specific therapeutic candidate. Monitoring this metric is essential for assessing the burn rate and capital efficiency of the company's individual pipeline programs.
Ask your AI about Omeros's pde7 — total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude